NEXIEN BIOPHARMA, INC. Quarterly Debt-to-equity in % from Q3 2015 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Nexien Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q3 2024.
  • Nexien Biopharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -102 %, a 15.5% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -102 +18.7 +15.5% Sep 30, 2024
Q2 2024 -103 +30.2 +22.6% Jun 30, 2024
Q1 2024 -107 +44.4 +29.3% Mar 31, 2024
Q4 2023 -112 Dec 31, 2023
Q3 2023 -121 Sep 30, 2023
Q2 2023 -134 Jun 30, 2023
Q1 2023 -151 Mar 31, 2023
Q2 2017 106 +206 Jun 30, 2017
Q1 2017 -100 0 0% Mar 31, 2017
Q4 2016 -100 -1.85 -1.89% Dec 31, 2016
Q3 2016 -100 -2.04 -2.08% Sep 30, 2016
Q2 2016 -100 Jun 30, 2016
Q1 2016 -100 Mar 31, 2016
Q4 2015 -98.2 Dec 31, 2015
Q3 2015 -98 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.